Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://app.periodikos.com.br/journal/medjpps/article/doi/10.5281/zenodo.7771314

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Opinion

Improvement of opioid addiction medication through extended-release naltrexone: a comparative, experimental and laboratory approach

Stephanos Schafer-Kavvadias

Downloads: 0
Views: 59

Abstract

Numerous health and social relationship problems, namely an increased risk of contracting HIV, mortality, crime, unemployment and impaired interpersonal relationships, are related to drug dependence, with opioids at the helm. For this reason, opioid addiction is considered a major public health problem [1] and is characterized as a ‘chronic relapsing disease’ and is a major concern for public health, as are drug and alcohol addictions [1, 2]. In addition to social support and psychotherapy, treatment of opioid dependence relies on medication intake. The three main opioid-dependence treatment categories include opioid agonists, opioid antagonists, and non-opioid medications. Naltrexone hydrochloride (API), one of the most commonly used medications relies on an opioid antagonist. It reduces opioid cravings, it can be administered outside the hospital setting and cannot be abused [3]. However, during treatment several patients often forget to take a dose, doubling the next dose to compensate. In some cases, this finding in the therapeutic levels not being reached, while in other cases undesired (side) effects appear. For this reason, especially in the case of long-term treatments of numerous diseases, an extended dosing interval is recommended, so that the patient receives the drug, only once a day, instead of two or three times a day.

Keywords

Extended-release, naltrexone, opioid antagonists, opioid-dependence treatment

References

  1. Haug NA, Sorensen JL, Gruber VA, Song YS (2005) Relapse prevention for opioid dependence (Ed. Marlatt GA, Donovan DM) In: Relapse prevention: maintenance strategies in the treatment of addictive behaviors. 151-178. 2nd Ed., New York, Guilford Press. ISBN: 1-59385-176-6.
  2. Voon V, Grodin E, Mandali A, Morris L, Donamayor N, Weidacker K, Kwako L, Goldman D, Koob GF, Momenan R (2020) Addictions neuroimaging assessment (ANIA): towards an integrative framework for alcohol use disorder. Neuroscience and Biobehavioral Reviews Journal. 113: 492-506. doi: 10.1016/j.neubiorev.2020.04.004.
  3. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2006) Oral naltrexone maintenance treatment for opioid dependence. The Cochrane Database of Systematic Reviews. 2011 (4): CD001333. doi: 10.1002/14651858.CD001333.pub4.
  4. Perrie Y, Rades T, Graeser K (2016) Principles of controlled release (Ed. Hillery AM, Park K) Drug delivery: Fundamentals and applications. 25-46. 2nd Ed., Tylor and Francis Group. doi.org/10.1201/9781315382579.
  5. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry. 63 (2): 210-218. doi: 10.1001/archpsyc.63.2.210.
  6. Van de Brink W, Haasen C (2006) Evidence-based treatment of opioid-dependent patients. Canada Journal of Psychiatry. 51 (10): 635-646. doi: 10.1177/070674370605101003.
  7. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P (2005) On the use of the Weibull function for the discernment of drug release mechanisms. International Journal of Pharmaceutics. 309 (1-2): 44-50. doi: 10.1016/j.ijpharm.2005.10.044.
  8. Efentakis M, Vlachou M (2000) Evaluation of high molecular weight poly (oxyethylene) (Polyox) polymer: studies of flow properties and release rates of furosemide and captopril from controlled-release hard gelatin capsules. Pharmaceutical Development and Technology. 5 (3): 39-46. doi: 10.1081/pdt-100100549.
  9. Vlachou M, Hani N, Efentakis M, Tarantili PA, Andreopoulos AG (2000) Polymers for use in controlled release systems: the effect of surfactants on their swelling properties. Journal of Biomaterials Applications. 15 (1): 65-77. doi: 10.1106/GX1T-2JC6-QWC6-69GC.
  10. Schafer-Kavadias S, Stratigakis Α (2021) Studies of extended-release naltrexone hydrochloride (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride) from solid dosage forms. Working paper as part of a thesis at the Laboratory of Pharmaceutical Technology.  Marilena Vlachou, National and Kapodistrian University of Athens, Athens, Greece.
  11. Lobmaier P, Kornor H, Kunoe N, Bjorndal A (2008) Sustained-release naltrexone for opioid dependence. The Cochrane Database of Systematic Reviews. 2: CD006140. doi: 10.1002/14651858.CD006140.pub2.

Submitted date:
01/07/2023

Reviewed date:
01/13/2023

Accepted date:
01/13/2023

Publication date:
07/17/2023

64b5a532a9539548d57e9746 medjpps Articles
Links & Downloads

Mediterr J Pharm Pharm Sci

Share this page
Page Sections